Match!
Nicolaas I. Bohnen
University of Michigan
DopaminergicDiseaseDementiaParkinson's diseaseMedicine
280Publications
52H-index
8,387Citations
What is this?
Publications 300
Newest
#1Uros Marusic (UM: University of Michigan)
#2Martijn L.T.M. Müller (UM: University of Michigan)H-Index: 28
Last. Nicolaas I. BohnenH-Index: 52
view all 4 authors...
BACKGROUND Physical inactivity is prevalent in older adults with type 2 diabetes mellitus (T2DM) and may exacerbate their clinical symptoms. The aim of this study was to examine the feasibility of 4-h regular versus more dynamic standing sessions while performing routine desktop activities as a non-exercise physical activity intervention in older adults with T2DM to increase non-exercise activity. METHODS Twelve older adult patients with T2DM (3 female; age 71 ± 4 years; Body mass index 34 ± 5 k...
Source
Objectives:The authors investigated the topography of cholinergic vulnerability in patients with dementia with Lewy bodies (DLB) using positron emission tomography (PET) imaging with the vesicular ...
Source
Source
#1Zhi ZhouH-Index: 1
Last. Nicolaas I. BohnenH-Index: 52
view all 9 authors...
Objective To determine whether β-amyloidopathy correlates with apathy rating scores independently of mood changes and other neurodegenerative processes in Parkinson disease (PD). Methods In this cross-sectional study, patients with PD (n = 64, 48 male and 16 female, mean age 69.2 ± 6.7 years, Hoehn & Yahr stage 2.7 ± 0.5, Montreal Cognitive Assessment score 25.3 ± 3.0) underwent [11C]Pittsburgh compound B β-amyloid, [11C]dihydrotetrabenazine vesicular monoamine transporter type 2 (VMAT2), and [1...
1 CitationsSource
#1Nicolaas I. Bohnen (UM: University of Michigan)H-Index: 52
#2Roger L. Albin (UM: University of Michigan)H-Index: 66
Source
#1Daniel Weiss (University of Tübingen)H-Index: 11
#2Anna Schoellmann (University of Tübingen)
Last. Simon J.G. Lewis (USYD: University of Sydney)H-Index: 43
view all 8 authors...
Diverse but complementary methodologies are required to uncover the complex determinants and pathophysiology of freezing of gait. To develop future therapeutic avenues, we need a deeper understanding of the disseminated functional-anatomic network and its temporally associated dynamic processes. In this targeted review, we will summarize the latest advances across multiple methodological domains including clinical phenomenology, neurogenetics, multimodal neuroimaging, neurophysiology, and neurom...
1 CitationsSource
#1Nicolaas I. BohnenH-Index: 52
#2Martijn L.T.M. Müller (UM: University of Michigan)H-Index: 28
The etiology of falls is multifactorial and hence a single treatment intervention is unlikely to be effective for falling. Cognitive enhancer pharmacotherapy may be of potential benefit to reduce fall risk in older adults with evidence of cognitive impairment. Data from subjects with Parkinson disease (PD) indicate significant reductions in falls with cholinergic augmentation therapy, especially in those with more frequent falls. Preliminary data from cholinesterase inhibitor treatment in patien...
Source
#1Martijn L.T.M. Müller (UM: University of Michigan)H-Index: 28
#2Uros Marusic (Alma Mater Europaea)H-Index: 7
Last. Nicolaas I. BohnenH-Index: 52
view all 5 authors...
AbstractIntroduction: Gait and balance disorders in Parkinson’s disease (PD) represent a major therapeutic challenge as frequent falls and freezing of gait impair quality of life and predict mortal...
Source
#2Angelo AntoniniH-Index: 70
#3Daniela BergH-Index: 65
Last. James B. Rowe (University of Cambridge)H-Index: 57
view all 29 authors...
Abstract Introduction Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials ...
1 CitationsSource
12345678910